A PHASE I/II TRIAL OF IBRUTINIB, INTRATUMORAL CPG AND LOCAL RADIATION IN PATIENTS WITH LOW‐GRADE B‐CELL LYMPHOMA: INTERIM CLINICAL AND CORRELATIVE RESULTS
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.82_2629
Abstract: lets >40,000/μL, adequate renal and hepatic function and no significant cardiac disease. Growth factors, transfusion and anticoagulation were allowed. The primary efficacy endpoint was objective response using 2007 International Working Group criteria. Results: As of… read more here.
Keywords: cll; cell; response; cll sll ... See more keywords
Infectious complications in CLL/SLL patients receiving Bruton's Tyrosine Kinase inhibitors – systematic review and meta-analysis of randomized controlled trials
Sign Up to like & getrecommendations! Published in 2025 at "Annals of Hematology"
DOI: 10.1007/s00277-025-06502-y
Abstract: The development of Bruton Tyrosine Kinase inhibitors (BTKis) has revolutionized the management of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). However, increased infection rates have been reported in patients receiving BTKis in multiple clinical trials. This… read more here.
Keywords: anti cd20; risk; tyrosine kinase; sll patients ... See more keywords
Suboptimal cancer-screening adherence in CLL/SLL patients
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-4536
Abstract: Background: Patients diagnosed with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have an increased risk of developing secondary primary malignancies. Several mechanisms have been proposed for this association which include genomic instability, impaired DNA repair and… read more here.
Keywords: cancer; sll patients; cll sll; cancer screening ... See more keywords